IDT Australia Limited reported sales results for the third quarter ended March 2023. For the quarter, revenue jumped 26% to $2.14 million over the previous quarter (and +168% over two quarters) due primarily to contracts won in IDT's Specialty Orals division. The demand outlook for Specialty Orals manufacturing is growing due to several factors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0925 AUD | +1.65% | -2.63% | -15.91% |
Apr. 16 | IDT Australia Signs Master Service Agreement with Sanofi | MT |
Feb. 21 | IDT Australia Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-15.91% | 21.5M | |
-1.43% | 104B | |
+8.96% | 105B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- IDT Stock
- News IDT Australia Limited
- IDT Australia Limited Reports Sales Results for the Third Quarter Ended March 2023